In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Terminating the induced atrial tachyarrhythmia after complete pulmonary vein isolation during catheter ablation for persistent atrial fibrillation

Session Poster Session 2

Speaker Yong-Seog Oh

Congress : ESC Congress 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Rhythm Control, Catheter Ablation
  • Session type : Poster Session
  • FP Number : P1902

Authors : Y Choi (Seoul,KR), SH Kim (Seoul,KR), SH Kim (Seoul,KR), JY Kim (Uijeongbu,KR), YR Kim (Incheon,KR), TS Kim (Daejeon,KR), YM Hwang (Suwon,KR), JH Kim (Suwon,KR), SW Jang (Seoul,KR), TH Rho (Seoul,KR), MY Lee (Seoul,KR), YS Oh (Seoul,KR)

Authors:
Y. Choi1 , S.H. Kim1 , S.H. Kim1 , J.Y. Kim2 , Y.R. Kim3 , T.S. Kim4 , Y.M. Hwang5 , J.H. Kim5 , S.W. Jang6 , T.H. Rho6 , M.Y. Lee1 , Y.S. Oh1 , 1Seoul St. Mary's Hospital, Division of Cardiology, Department of Internal Medicine - Seoul - Korea Republic of , 2Uijeongbu St. Mary's Hospital, Division of Cardiology, Department of Internal Medicine - Uijeongbu - Korea Republic of , 3St.Mary's Hospital, Division of Cardiology, Department of Internal Medicine - Incheon - Korea Republic of , 4Daejeon St. Mary's Hospital, Division of Cardiology, Department of Internal Medicine - Daejeon - Korea Republic of , 5St. Vincent's Hospital, Division of Cardiology, Department of Internal Medicine - Suwon - Korea Republic of , 6St.Paul's Hospital, Division of Cardiology, Department of Internal Medicine - Seoul - Korea Republic of ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 407

Background: Acute arrhythmia termination during radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF) was shown to be associated with a better procedure outcome. However, whether acute termination could be a reliable endpoint during ablation for induced atrial tachyarrhythmia is unknown.

Objective: The aim of this study was to evaluate the impact of acute arrhythmia termination in patients with persistent AF and having inducible arrhythmia after complete pulmonary vein isolation (PVI).

Methods: Among patients undergoing RFCA for persistent AF, 157 patients with continued atrial tachyarrhythmia after PVI and 93 patients who showed sinus rhythm after PVI and had inducible atrial tachyarrhythmia were enrolled. The impact of acute arrhythmia termination during further substrate modification on procedure outcome was compared between the two groups.

Results: Acute arrhythmia termination was achieved by further ablation in 51 (54.8%) in the induced arrhythmia group and 61 (38.9%) in the continued arrhythmia group. During a mean 35.8 months, acute arrhythmia termination did not significantly reduce long-term recurrence in the induced arrhythmia group [43.1% vs. 61.9%, hazard ratio (HR) 0.712, 95% confidence interval (CI) 0.400–1.266, p=0.247], while it was associated with a significantly lower arrhythmia recurrence in the continued arrhythmia group (34.4% vs. 55.2%, HR 0.590, 95% CI 0.355–0.979, p=0.038]. Among the overall population, acute arrhythmia termination was not an independent predictor for arrhythmia freedom in multivariate analysis.

Conclusion: In patients with inducible arrhythmia after PVI, further substrate modification targeting termination of induced rhythm may not be an effective ablation strategy during RFCA for persistent AF.

Figure 1. Impact of acute termination

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are